CytomX Therapeutics, Inc. Forecast, price target & analysts
CytomX Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation
CytomX Therapeutics, Inc. Classifications & Recommendation
CytomX Therapeutics, Inc. Price Target
| Target Price | $12.24 |
| Price | $2.56 |
| Potential |
378.13%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target CytomX Therapeutics, Inc. 2027 .
The average CytomX Therapeutics, Inc. target price is $12.24.
This is
378.13%
register free of charge
$16.80
556.25%
register free of charge
$6.06
136.72%
register free of charge
|
|
| A rating was issued by 14 analysts: 13 Analysts recommend CytomX Therapeutics, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the CytomX Therapeutics, Inc. stock has an average upside potential 2027 of
378.13%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 76.20 | 30.61 |
| 44.82% | 59.82% | |
| EBITDA Margin | -23.87% | -291.53% |
| 223.19% | 1,121.25% | |
| Net Margin | -26.73% | -280.42% |
| 215.84% | 948.99% |
9 Analysts have issued a sales forecast CytomX Therapeutics, Inc. 2026 . The average CytomX Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an CytomX Therapeutics, Inc. EBITDA forecast 2026. The average CytomX Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 CytomX Therapeutics, Inc. Analysts have issued a net profit forecast 2026. The average CytomX Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.15 | -0.39 |
| 139.47% | 160.00% | |
| P/E | negative | |
| EV/Sales | 7.43 |
10 Analysts have issued a CytomX Therapeutics, Inc. forecast for earnings per share. The average CytomX Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
CytomX Therapeutics, Inc....
Current CytomX Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 13 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 10 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 11 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Mar 23 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Mar 19 2026 |
| Jefferies |
Locked
➜
Locked
|
Locked | Mar 18 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Mar 18 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 13 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 10 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 11 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Mar 23 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Mar 19 2026 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Mar 18 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Mar 18 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
